Products for Research Use Only

Zetomipzomib

CAT: 0804-HY-114419-01Size: 1 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-114419-01Size:1 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Zetomipzomib (KZR-616), a first-in-class inhibitor of the immunoproteasome, selectively targets the LMP7 (IC50: 39/57 nM=hLMP7/mLMP7) and LMP2 (IC50: 131/179 nM=hLMP7/mLMP7) subunits of the immunoproteasome. Zetomipzomib has the potential for the research of multiple autoimmune diseases[1][2].
CAS Number
1629677-75-3
Product Name Alternative
KZR-616
UNSPSC
12352005
Target
Proteasome
Type
Reference compound
Related Pathways
Metabolic Enzyme/Protease
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/kzr-616.html
Purity
99.89
Solubility
DMSO : 50 mg/mL
Smiles
O=C(N[C@@H](CC1=CCCC1)C([C@]2(C)OC2)=O)[C@@H](NC([C@@H](NC(CN3CCOCC3)=O)C)=O)[C@H](O)C4=CC=C(OC)C=C4
Molecular Formula
C30H42N4O8
Molecular Weight
586.68
References & Citations
[1]Johnson HWB, et al. Required Immunoproteasome Subunit Inhibition Profile for Anti-Inflammatory Efficacy and Clinical Candidate KZR-616 ((2 S,3 R) - N- ((S) -3- (Cyclopent-1-en-1-yl) -1- ((R) -2-methyloxiran-2-yl) -1-oxopropan-2-yl) -3-hydroxy-3- (4-methoxyphenyl) -2- ((S) -2- (2-morpholinoacetamido) propanamido) propenamide) . J Med Chem. 2018 Dec 27;61 (24) :11127-11143.|[2]Muchamuel T, et al. FRI0296 Kzr-616, a selective inhibitor of the immunoproteasome, blocks the disease progression in multiple models of systemic lupus erythematosus (SLE) . Annals of the Rheumatic Diseases 2018;77:685.|[3]Xi J, et al. Immunoproteasome-selective inhibitors: An overview of recent developments as potential drugs for hematologic malignancies and autoimmune diseases. Eur J Med Chem. 2019;182:111646.
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, sealed storage, away from moisture)
Scientific Category
Reference compound1
Clinical Information
Phase 2